Herein, we describe the exploration of 3 biomarkers—human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24—as potential radiotheranostic targets for endometrial cancer. This evidence concerns the gene MUC16 and endometrial cancer.